Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 18, 2026

Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider

View original at globenewswire.com
Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The U.S. Turner Syndrome Market size was valued at an estimated USD 0.52 Billion in 2025 and is projected to reach USD 0.96 Billion by 2033, growing at a CAGR of 8.12% over the forecast period 2026–2033

    80% confidence

  • Turner syndrome occurs in 1 out of every 2,500 female newborns

    80% confidence

  • North America dominated the Turner syndrome market in 2025 with a 37.70% revenue share

    80% confidence

  • The Asia-Pacific region is expected to grow at the highest CAGR of 9.43%

    80% confidence

  • The Turner Syndrome Market was valued at USD 1.93 Billion in 2025 and is projected to reach USD 3.67 Billion by 2033, reflecting a compound annual growth rate (CAGR) of 8.39% from 2026 to 2033

    80% confidence

  • The U.S. leads globally in orphan drug approvals for chromosomal conditions

    80% confidence

  • A majority of Turner syndrome patients are unaware of their condition until they enter adolescence

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider — Source | Via News | ViaNews EU